A Phase 2 Study of XmAb23104 in People With Sarcoma


Full Title

Phase II study of XmAb23104 (targeting PD-1 and ICOS), in Patients with Advanced Sarcoma


In this study, researchers want to assess the safety of XmAb23104 and see how well it works to treat advanced sarcoma. This study is for people with sarcoma that keeps growing even after treatment. It is also for people who could not have standard sarcoma treatment or who decided not to have it.

XmAb23104 is a type of immunotherapy. That means it boosts the power of the immune system to fight cancer. XmAb23104 helps your own immune cells fight and kill tumor cells. It is given intravenously (by vein).

Who Can Join

To join this study, there are a few conditions. You must:

  • Have 1 of these types of sarcoma: dedifferentiated liposarcoma (DDLPS), leiomyosarcoma (LMS), dedifferentiated chondrosarcoma (DDCS), alveolar soft part sarcoma (ASPS), sclerosing epithelioid fibrosarcoma (SEF), or pecoma.
  • Have sarcoma that standard therapies cannot treat successfully.
  • Have no serious side effects from your past treatments before you start taking XmAb23104.
  • Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
  • Be age 18 and older.


For more information and to see if you can join this study, please contact Dr. Ciara Kelly’s office at 646-888-4312.





Disease Status

Relapsed or Refractory



ClinicalTrials.gov ID